Cargando…

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer

We examined a large dataset of female metastatic breast cancers (MBCs) profiled with comprehensive genomic profiling (CGP) to identify the prevalence and distribution of immunotherapy responsiveness‐associated biomarkers. DNA was extracted from 3831 consecutive MBCs: 1237 (ER(pos)/HER2 (neg)), 1953...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sivapiragasam, Abirami, Ashok Kumar, Prashanth, Sokol, Ethan S., Albacker, Lee A., Killian, Jonathan K., Ramkissoon, Shakti H., Huang, Richard S. P., Severson, Eric A., Brown, Charlotte A., Danziger, Natalie, McGregor, Kimberly, Ross, Jeffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826457/ https://www.ncbi.nlm.nih.gov/pubmed/33314633 http://dx.doi.org/10.1002/cam4.3550

Ejemplares similares

Genomic landscape of non‐small‐cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers
por: Girard, Nicolas, et al.
Publicado: (2022)

Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study
por: Bratslavsky, Gennady, et al.
Publicado: (2021)

Primary Mucinous Adenocarcinoma of the Upper Eyelid in an African American Female: A Rare Clinical Entity. A Case Report and Literature Review
por: Ashok Kumar, Prashanth, et al.
Publicado: (2019)

Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors
por: Ramkissoon, Lori A., et al.
Publicado: (2020)

Molecular Targets in Salivary Gland Cancers: A Comprehensive Genomic Analysis of 118 Mucoepidermoid Carcinoma Tumors
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study
por: Ashok Kumar, Prashanth, et al.
Publicado: (2021)

Current Trends in the Management of Epithelial Lacrimal Gland Tumors: A Retrospective National Cancer Database Analysis
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

Ductal Adenocarcinoma Ex Pleomorphic Adenoma of the Lacrimal Gland: a Rare and Morbid Malignancy
por: Ashok Kumar, Prashanth, et al.
Publicado: (2020)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
por: Sandhu, Michael, et al.
Publicado: (2023)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
por: Huang, Richard S. P., et al.
Publicado: (2021)

Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations
por: Papillon-Cavanagh, Simon, et al.
Publicado: (2021)

Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
por: Riess, Jonathan W., et al.
Publicado: (2021)

Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV– Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets
por: Williams, Erik A., et al.
Publicado: (2020)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
por: Abou Alaiwi, Sarah, et al.
Publicado: (2020)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation
por: Huang, Richard S P, et al.
Publicado: (2022)

Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma
por: Foijer, Floris, et al.
Publicado: (2017)

Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study
por: Necchi, Andrea, et al.
Publicado: (2022)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
por: Board, Ruth, et al.
Publicado: (2020)

Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer
por: Murugesan, Karthikeyan, et al.
Publicado: (2022)

The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors
por: Rinaldi, Jacob, et al.
Publicado: (2020)

Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer
por: Basnet, Alina, et al.
Publicado: (2017)

CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion
por: Williams, Erik A., et al.
Publicado: (2020)

FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
por: Park, Hyo Jung, et al.
Publicado: (2022)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g2o914vlvl2oi5k64uorrgn8q0